Editing Daiichi Sankyo Company, Limited
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 176: | Line 176: | ||
HER3-DXd is a novel ADC, which specifically targets HER3. In a study 57 patients recieving HER3-DXd the <u>objective response rate</u>**** was found to be 39% and the median <u>progression-free survival</u>***** was 8.2 months. Responses were also observed in patients with known and unknown EGFR TKI resistance mechanisms<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401524/</ref> | HER3-DXd is a novel ADC, which specifically targets HER3. In a study 57 patients recieving HER3-DXd the <u>objective response rate</u>**** was found to be 39% and the median <u>progression-free survival</u>***** was 8.2 months. Responses were also observed in patients with known and unknown EGFR TKI resistance mechanisms<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401524/</ref> | ||
A list of | A list of T-DXd drugs currently in clinical trials can be found [https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/pipeline2304_en.pdf here] in green. | ||